Quick access to up-to-date company information.
Boehringer Ingelheim Submits Biologics License Application to FDA for Idarucizumab*, Investigational Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)
New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function, Regardless of Allergic Status
New Survey Uncovers Emotional and Physical Impact of Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease
Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
Click here to subscribe to email press release alerts
900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877